<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Differentiated thyroid cancer: Role of serum thyroglobulin
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Differentiated thyroid cancer: Role of serum thyroglobulin
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Differentiated thyroid cancer: Role of serum thyroglobulin
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Author:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            R Michael Tuttle, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editors:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            David S Cooper, MD
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Douglas S Ross, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Jean E Mulder, MD
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Jun 27, 2023.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H1">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Thyroglobulin (Tg) is a storage form of thyroxine (T4) and triiodothyronine (T3). It is synthesized only by thyroid follicular cells and released into serum along with the thyroid hormones. Given the cellular specificity of Tg, its detection in biopsy specimens provides proof of the thyroid origin of the tissue. In addition, measurements of serum Tg provide important information about the presence or absence of residual, recurrent, or metastatic disease in patients with differentiated thyroid cancer. This topic review will describe the methods for measuring serum Tg and the use of serum Tg measurements in patients with differentiated thyroid cancer. Other aspects of the management of thyroid cancer are reviewed separately. (See
         <a class="medical medical_review" href="/z/d/html/7838.html" rel="external">
          "Differentiated thyroid cancer: Overview of management"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2">
         <span class="h1">
          THYROGLOBULIN ASSAY
         </span>
         <span class="headingEndMark">
          —
         </span>
         Testing of serum thyroglobulin (Tg) should be done using a sensitive assay, ideally using the same assay for each sample.
        </p>
        <p class="headingAnchor" id="H3">
         <span class="h2">
          Methodology
         </span>
         <span class="headingEndMark">
          —
         </span>
         Serum Tg is now generally measured by two-antibody "sandwich" immunometric assays (the antigen is sandwiched between the two antibodies) in which the capture antibody is bound to a solid support and the detection antibody is labeled with either an isotopic (immunoradiometric assay, IRMA) or non-isotopic (usually immunochemiluminescent assay, ICMA) marker. The values in normal subjects in most laboratories range from 1 to approximately 30 ng/mL. These immunometric assays are quicker, readily automated, and have greater sensitivity (0.1 to 1 ng/mL) than most radioimmunoassays [
         <a href="#rid1">
          1
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H4">
         <span class="h2">
          Interassay variation
         </span>
         <span class="headingEndMark">
          —
         </span>
         We recommend that serial Tg measurements in thyroid cancer patients be done using the same assay.
        </p>
        <p>
         Despite a trend toward assay standardization, serum Tg values obtained with different assays cannot be directly compared, as interassay variability remains substantial [
         <a href="#rid2">
          2-4
         </a>
         ]. The variability in assay results is due to [
         <a href="#rid1">
          1,5-7
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Variations in the anti-Tg antibodies used.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The heterogeneity of Tg, a consequence of alternative processing and differences in iodination of Tg.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Tg produced by thyroid cancer cells can be even more heterogeneous (because of dysregulation of the enzymatic glycosylation and iodination within malignant thyroid cells) and occasionally has enough conformational difference that it may not be recognized by a standard Tg assay.
        </p>
        <p>
        </p>
        <p>
         The net effect can be widely variable antigen (Tg) detection among different assays.
        </p>
        <p class="headingAnchor" id="H5">
         <span class="h2">
          Intraassay variation
         </span>
         <span class="headingEndMark">
          —
         </span>
         Even using the same assay, between-run variability can affect the comparability of serial determinations over time [
         <a href="#rid2">
          2,8
         </a>
         ]. While these differences are far less than the between-assay differences, they can be responsible for small fluctuations in Tg measurements over time within the same patient.
        </p>
        <p class="headingAnchor" id="H6">
         <span class="h2">
          Functional sensitivity
         </span>
         <span class="headingEndMark">
          —
         </span>
         Functional sensitivity is defined as the lowest Tg concentration that an assay can reliably and consistently measure under clinically relevant conditions with less than 20 percent coefficient of variation. For many years, the functional sensitivity of most Tg assays had been approximately 0.9 ng/mL. However, several assays with functional sensitivities of 0.1 to 0.2 ng/mL are commercially available [
         <a href="#rid4">
          4,9,10
         </a>
         ].
        </p>
        <p>
         To further enhance the sensitivity of serum Tg in the detection of persistent/recurrent thyroid cancer, serum Tg levels can be measured during thyroid-stimulating hormone (TSH) stimulation (either thyroid hormone withdrawal or with recombinant human TSH [rhTSH, thyrotropin alfa] administration) [
         <a href="#rid11">
          11
         </a>
         ]. When using the less sensitive assays (functional sensitivities of approximately 1 ng/mL), TSH stimulation will result in a previously undetectable serum Tg value becoming measurable in as many as 20 to 25 percent of patients [
         <a href="#rid12">
          12
         </a>
         ].
        </p>
        <p>
         In the newer, more sensitive Tg assays, serum Tg concentrations (measured while receiving
         <a class="drug drug_general" data-topicid="9557" href="/z/d/drug information/9557.html" rel="external">
          levothyroxine
         </a>
         [T4, thyroxine] suppression therapy) correlate with rhTSH-stimulated Tg concentrations and, therefore, decrease the need for rhTSH-stimulated measurements [
         <a href="#rid4">
          4,9,13-16
         </a>
         ]. This was illustrated in a study of 849 Tg antibody-negative patients being monitored after treatment for differentiated thyroid cancer [
         <a href="#rid9">
          9
         </a>
         ]. Patients with a TSH-suppressed serum Tg concentration &lt;0.1 ng/mL (measured with an assay with a functional sensitivity of 0.05 ng/mL) were unlikely to have an rhTSH stimulated Tg above 2.0 ng/mL. Similar findings were noted in a study of 178 low-risk patients that compared basal and post thyroid hormone withdrawal Tg levels. Basal serum Tg levels were &lt;0.1 ng/mL in 130 patients. After withdrawal of thyroid hormone, 5 of 130 (3.8 percent) had a Tg &gt;1 ng/mL and recurrence was diagnosed in only one patient. Among the 48 patients with Tg &gt;0.1 ng/mL, 42 percent had Tg &gt;1 ng/mL after withdrawal and 11 percent had recurrences [
         <a href="#rid15">
          15
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H7">
         <span class="h2">
          Hook effect
         </span>
         <span class="headingEndMark">
          —
         </span>
         Occasionally, immunometric assays may fail to detect very high serum Tg concentrations due to the so-called "hook effect," in which extremely high concentrations of Tg bind to each antibody, preventing the formation of the two-antibody sandwich upon which the assay depends [
         <a href="#rid17">
          17
         </a>
         ]. If this effect is suspected, the sample should be reanalyzed after dilution to obtain a reliable Tg measurement.
        </p>
        <p class="headingAnchor" id="H61487632">
         <span class="h2">
          Heterophilic antibodies
         </span>
         <span class="headingEndMark">
          —
         </span>
         False-positive Tg results have been reported as a result of interference by heterophilic anti-mouse antibodies (HAMA) in an immunometric assay [
         <a href="#rid18">
          18
         </a>
         ]. In this report, approximately 3 percent of the 1100 blood specimens tested had substantial differences in the measured Tg value before and after the specimens were treated to block potential heterophile antibody interference.
        </p>
        <p>
         While an uncommon clinical problem, the presence of HAMA antibody interference should be considered in patients in whom an elevated Tg does not seem appropriate for their clinical condition [
         <a href="#rid19">
          19
         </a>
         ]. Since radioimmunoassay is very unlikely to be affected by HAMA antibodies, repeat determination with a radioimmunoassay technique is likely to reveal the true serum Tg level [
         <a href="#rid20">
          20
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H1731648033">
         <span class="h2">
          Potential assay interference with biotin
         </span>
         <span class="headingEndMark">
          —
         </span>
         Some automated assays utilizing a biotin-streptavidin separation system report falsely low or falsely high Tg levels. As an example, in one report,
         <a class="drug drug_general" data-topicid="120386" href="/z/d/drug information/120386.html" rel="external">
          biotin
         </a>
         (10 mg/day) was associated with a falsely lower Tg value, with maximal biotin interference observed two hours after ingestion of the biotin [
         <a href="#rid21">
          21
         </a>
         ]. While additional studies are needed to clarify the likelihood of biotin interference associated with various biotin doses commonly being used as over-the-counter products in an effort to improve hair and joint health, repeating Tg values in the absence of biotin supplementation for at least two days can be considered if the measured Tg value is not consistent with the clinical scenario.
        </p>
        <p class="headingAnchor" id="H9">
         <span class="h1">
          THYROGLOBULIN ANTIBODIES
         </span>
         <span class="headingEndMark">
          —
         </span>
         We recommend measuring antithyroglobulin (anti-Tg) antibodies with each measurement of serum Tg. Anti-Tg antibodies are detectable in as many as 10 percent of the general population [
         <a href="#rid22">
          22
         </a>
         ] and 20 percent of thyroid cancer patients [
         <a href="#rid1">
          1,23
         </a>
         ]. These antibodies represent a challenge, because thyroglobulin (Tg) values obtained in the presence of anti-Tg antibodies may not be clinically reliable. Just as with serum Tg measurements, anti-Tg antibody levels are dependent upon the assay used, and serial values need to be compared within the same assay.
        </p>
        <p>
         In patients with anti-Tg antibodies, serum Tg concentrations alone cannot be used as a marker to detect persistent or recurrent disease after thyroidectomy and ablation of residual normal thyroid tissue (see
         <a class="local">
          'Monitoring response to therapy'
         </a>
         below). Nevertheless, serum Tg and anti-Tg antibodies should be measured as in patients without Tg antibodies because disease recurrence can be heralded by a rise in Tg antibodies with or without a corresponding rise in serum Tg. (See
         <a class="local">
          'Surrogate tumor marker'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H10">
         <span class="h2">
          Impact on Tg assay
         </span>
         <span class="headingEndMark">
          —
         </span>
         Because anti-Tg antibodies can have a major impact on the measurement of serum Tg, all laboratories that measure serum Tg should test for anti-Tg antibodies in any serum sample submitted for Tg assay [
         <a href="#rid24">
          24
         </a>
         ].
        </p>
        <p>
         By binding with the circulating serum Tg, anti-Tg antibodies may decrease the amount of unbound (free) Tg available for detection. Since immunometric assay systems appear to detect only the unbound (free) Tg, this effect can result in falsely low values. The magnitude of the interference is most noticeable at low Tg levels where the immunometric assays can falsely report an undetectable serum Tg if the anti-Tg antibodies are competing for the low-level circulating Tg molecules. This effect is not abrogated by use of monoclonal antibodies directed against epitopes of Tg that do not react with the autoantibodies [
         <a href="#rid25">
          25
         </a>
         ]. Even very low anti-Tg antibody levels can interfere with the Tg assay performance. There does not appear to be a threshold value of anti-Tg antibodies that is predictive of antibody interference [
         <a href="#rid1">
          1
         </a>
         ]. In some anti-Tg antibody assays, more reliable results are obtained if any level above the analytic sensitivity of the assay is considered to be Tg antibody-positive rather than using the manufacturer recommended cut-off levels [
         <a href="#rid26">
          26
         </a>
         ].
        </p>
        <p>
         Conversely, radioimmunoassays tend to report falsely high Tg values in the presence of anti-Tg antibodies. This is probably because, unlike the immunometric assay, the radioimmunoassay detects both unbound (free) Tg and bound Tg (complexed to anti-Tg antibodies). As a result, the Tg value reported may be higher than the actual "free" Tg circulating in the blood stream but is much less likely to be false low value. Because of this discordance between radioimmunoassay and immunometric assays, some experts have recommended that in the presence of anti-Tg antibodies, radioimmunoassays should be used to measure the serum Tg (recognizing the possibility of a false high result) but assuming a low value is likely to be real and reflect the clinical situation [
         <a href="#rid20">
          20
         </a>
         ]. While this approach appears to be valid, radioimmunoassays are not widely available and still need to be interpreted with caution in this setting.
        </p>
        <p>
         In an attempt to determine whether a circulating anti-Tg antibody is causing assay interference, several commercial labs offer Tg measurements by recovery assays, using standard immunometric assays to determine serum Tg levels before and after addition of a known amount of Tg. If 80 to 120 percent of the added quantity of Tg is detected, the antibodies are not considered to be interfering and a Tg value is reported. If the value falls outside that range, antibody interference is assumed and no Tg value is reported. While these assays have gained popularity in both the United States and Europe, many experts feel strongly that recovery assays are not reliable [
         <a href="#rid20">
          20
         </a>
         ].
        </p>
        <p>
         Assays using liquid chromatography-tandem mass spectrometry (LC-MS/MS) for the measurement of serum Tg are currently being evaluated. This technology uses trypsin to digest Tg bound to Tg antibody in order to release a specific target Tg peptide that can be enriched and subsequently detected by LC-MS/MS. While this assay was reported to detect Tg in the presence of anti-Tg antibodies [
         <a href="#rid27">
          27
         </a>
         ], another study found that LC-MS/MS failed to detect Tg in at least 40 percent of Tg antibody-positive patients with known structural disease [
         <a href="#rid28">
          28
         </a>
         ]. In addition, functional sensitivity (0.5 to 1.0 ng/mL) remains inferior to radioimmunoassays [
         <a href="#rid28">
          28,29
         </a>
         ]. The cause for an undetectable MS Tg reading in the setting of known structural disease has not been determined but could be related to a wide variety of factors, including suboptimal functional sensitivity, poor Tg secretion by some tumors, tumor Tg polymorphisms, or enhanced metabolic clearance of serum Tg-anti-Tg antibody complexes [
         <a href="#rid28">
          28-31
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H61487509">
         <span class="h2">
          Surrogate tumor marker
         </span>
         <span class="headingEndMark">
          —
         </span>
         Following total thyroidectomy and radioiodine ablation, serum anti-Tg antibodies usually fall to undetectable levels over three to five years, while patients with persistent disease typically maintain detectable or rising anti-Tg. The decline in anti-Tg antibody levels has prognostic significance as a &gt;50 percent decline during the first three years of follow-up is associated with a &lt;3 percent risk of recurrence [
         <a href="#rid30">
          30,32
         </a>
         ]. Stable values are associated with an approximately 20 percent risk of recurrence and rising values with approximately 40 percent risk of recurrence.
        </p>
        <p>
         In two studies of thyroid cancer patients with undetectable serum Tg concentrations, 18 and 49 percent of patients with serum anti-Tg antibody concentrations &gt;100 units/mL had a recurrence, compared with only 1 and 3 percent of patients with serum anti-Tg antibody concentrations &lt;100 units/mL [
         <a href="#rid32">
          32,33
         </a>
         ]. Even in patients previously documented to be free of anti-Tg antibodies, disease recurrence can be heralded by a rise in Tg antibodies with or without a corresponding rise in serum Tg [
         <a href="#rid20">
          20,33,34
         </a>
         ]. However, in a subsequent study evaluating 812 patients with undetectable Tg antibodies on at least three serial assays over a minimum of three years of follow-up, 5 percent (n = 40) of patients converted to having detectable Tg antibodies, which was not associated with an increased risk of structural disease recurrence when compared with the group that were consistently Tg antibody undetectable (n = 772 patients) [
         <a href="#rid35">
          35
         </a>
         ].
        </p>
        <p>
         Just as with serum Tg measurements, anti-Tg antibody levels are dependent upon the assay used, and serial values need to be compared within the same assay [
         <a href="#rid36">
          36
         </a>
         ]. In patients with coexistent autoimmune thyroid disease at the time of surgery, anti-Tg antibodies may persist far longer. In a study of 116 patients with anti-Tg antibodies prior to thyroidectomy, antibodies remained detectable for up to 20 years in some patients without detectable thyroid tissue, and the median time to disappearance of antibodies was three years [
         <a href="#rid37">
          37
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H12">
         <span class="h1">
          MONITORING RESPONSE TO THERAPY
         </span>
        </p>
        <p class="headingAnchor" id="H1484279099">
         <span class="h2">
          When to measure
         </span>
         <span class="headingEndMark">
          —
         </span>
         Serum thyroglobulin (Tg) levels are used to monitor patients with differentiated thyroid cancer for persistent or recurrent disease after initial therapy (thyroidectomy with or without radioiodine ablation). Serum Tg can be measured while taking suppressive doses of thyroid hormone (TSH-suppressed) or with TSH stimulation (after thyroid hormone withdrawal or after administration of rhTSH). An important caveat pertains to patients in whom rhTSH, instead of withdrawal, is used for remnant ablation. In that protocol, radioiodine is given 48 hours before the measurement of the "stimulated" Tg, which may cause release of Tg from the remnants, potentially causing spuriously higher values [
         <a href="#rid38">
          38
         </a>
         ].
        </p>
        <p>
         A suggested schedule for Tg monitoring during the first year after thyroid surgery (
         <a class="graphic graphic_table graphicRef90173" href="/z/d/graphic/90173.html" rel="external">
          table 1
         </a>
         ) as well as for long-term monitoring of patients with differentiated thyroid cancer (
         <a class="graphic graphic_table graphicRef89724" href="/z/d/graphic/89724.html" rel="external">
          table 2
         </a>
         ) is discussed in more detail separately. (See
         <a class="medical medical_review" href="/z/d/html/7838.html" rel="external">
          "Differentiated thyroid cancer: Overview of management", section on 'Monitoring response to therapy'
         </a>
         .)
        </p>
        <p>
         The three major determinants of the serum Tg concentration are [
         <a href="#rid20">
          20
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The mass of thyroid tissue present (both normal and malignant thyroid cells)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The presence of injury to the thyroid (eg, after fine-needle aspiration [FNA], thyroidectomy or radioiodine therapy, or during thyroiditis)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The degree of TSH receptor stimulation (eg, endogenous TSH, rhTSH [thyrotropin alfa], serum human chorionic gonadotropin [hCG], TSH receptor antibodies associated with autoimmune thyroid disease)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H13">
         <span class="h2">
          Detecting persistent thyroid cancer
         </span>
         <span class="headingEndMark">
          —
         </span>
         Serum Tg measurements (post thyroidectomy) are useful for detecting persistent disease after initial treatment of differentiated thyroid cancer. Serum Tg measured before thyroidectomy is a reflection of both the normal and malignant thyroid cells and therefore is not a reliable predictor of thyroid cancer. Serum Tg is cleared with a half-life of approximately 30 hours following thyroidectomy [
         <a href="#rid39">
          39
         </a>
         ].
        </p>
        <p>
         The interpretation of the serum Tg level depends upon the initial therapy. (See
         <a class="medical medical_review" href="/z/d/html/7838.html" rel="external">
          "Differentiated thyroid cancer: Overview of management", section on 'Serum thyroglobulin measurements'
         </a>
         .)
        </p>
        <p>
         In patients with metastatic thyroid cancer, the serum Tg appears to be influenced by the volume of disease, the specific histology of the lesion, and the anatomic location of the metastasis. As an example, in a retrospective study of 417 thyroid cancer patients, basal Tg concentrations (TSH-suppressed) correlated with the volume and location of metastases (higher with bone and/or lung than cervical metastases), and with the histologic type of cancer (higher levels in follicular and Hürthle cell cancers compared with papillary cancers) [
         <a href="#rid40">
          40
         </a>
         ]. Stimulated Tg concentrations (in response to recombinant TSH) correlated only with histologic type of cancer (highest in papillary and lowest in Hürthle cell cancers).
        </p>
        <p>
         A meta-analysis found that the sensitivity and specificity of Tg measurement to detect persistent thyroid cancer was 96 and 95 percent, respectively, after thyroid hormone withdrawal; 93 and 88 percent, respectively, after rhTSH; and 78 and 98 percent, respectively, when measured while taking suppressive doses of thyroid hormone [
         <a href="#rid41">
          41
         </a>
         ]. Combining rhTSH stimulation with cervical ultrasound improved sensitivity and negative predictive value to 93 and 99 percent, respectively, in a study of 340 consecutive patients [
         <a href="#rid42">
          42
         </a>
         ]. These data indicate that neck ultrasonography will occasionally identify structural disease even when the Tg is undetectable.
        </p>
        <p class="headingAnchor" id="H14">
         <span class="h2">
          Detecting recurrent thyroid cancer
         </span>
         <span class="headingEndMark">
          —
         </span>
         Because serum Tg concentration is dependent on the mass of thyroid tissue present (both normal and malignant), serum Tg values have the highest sensitivity and specificity for detection of recurrent disease after the patient has had a total thyroidectomy and radioiodine ablation of any microscopic residual normal thyroid cells remaining after total thyroidectomy [
         <a href="#rid43">
          43-45
         </a>
         ]. However, serum Tg may be useful for identifying persistent or metastatic disease in patient undergoing thyroidectomy without radioiodine. In a systematic review of studies examining the utility of serum Tg for detection of recurrent disease in patients who had total or near-total thyroidectomy without radioiodine, Tg levels less than 1 to 2.5 ng/mL appeared to identify patients at low risk for persistent or metastatic disease [
         <a href="#rid46">
          46
         </a>
         ].
        </p>
        <p>
         Because Tg production and release from the cell are significantly influenced by the degree of TSH stimulation, it is not surprising that Tg measurements are likely to be more sensitive for detection of recurrent disease following TSH stimulation (endogenous TSH or rhTSH) than when measured during TSH suppression (on T4). Nevertheless, others have utilized T4-suppressed Tg measurements along with ultrasound to assess for disease recurrence. In one such study of 495 patients, a detectable Tg while taking T4 indicated recurrence in 23 of 44 patients, while the addition of ultrasound detected 42 of the 44 recurrences [
         <a href="#rid47">
          47
         </a>
         ].
        </p>
        <p>
         Although initial measurement of rhTSH-stimulated Tg is useful, repeat rhTSH-stimulated Tg testing in patients whose first stimulated Tg is undetectable may not be helpful. As an example, in one study of 68 patients with an rhTSH-stimulated Tg that was initially &lt;1 ng/mL at the time of remnant ablation, only 1 of 67 patients had a detectable stimulated value two to three years later [
         <a href="#rid48">
          48
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H15">
         <span class="h2">
          Predictor of clinical outcomes
         </span>
         <span class="headingEndMark">
          —
         </span>
         Serum Tg concentrations may predict disease-free remission at various times in the patient's course. The serum Tg concentration in low-risk patients after initial surgery while hypothyroid, just prior to administration of radioiodine for remnant ablation, has been correlated with patient outcomes [
         <a href="#rid49">
          49-51
         </a>
         ]. As an example, in a meta-analysis of 15 studies (3947 patients with differentiated thyroid cancer) evaluating TSH-stimulated (thyroid hormone withdrawal) Tg prior to radioiodine ablation, the negative predictive value of a serum Tg below a threshold of 10 ng/mL was 94.2 percent for the absence of disease recurrence [
         <a href="#rid52">
          52
         </a>
         ].
        </p>
        <p>
         In a study that assessed Tg levels months after remnant ablation and with up to five years of follow-up, recurrent tumor was identified in 1.6 percent of patients with initial Tg after rhTSH &lt;0.5 ng/mL, 5.5 percent of patients with Tg 0.6 to 2.0 ng/mL, and 80 percent of patients with Tg greater than 2.0 ng/mL [
         <a href="#rid53">
          53
         </a>
         ].
        </p>
        <p>
         It has become increasingly apparent that the results of repeated measurements of serum Tg over time are often more useful than a single measurement [
         <a href="#rid54">
          54,55
         </a>
         ]. A progressive increase in serum Tg concentrations strongly suggests progressive disease and should lead to a search for the disease, usually starting with a chest radiograph, neck ultrasonography, and radioiodine scanning. Serum Tg doubling time of less than one year was associated with significantly higher rates of 10-year, disease-specific mortality, locoregional metastases, and identification of distant metastases than Tg doubling times of one to three years or greater than three years [
         <a href="#rid56">
          56
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/7838.html" rel="external">
          "Differentiated thyroid cancer: Overview of management", section on 'Monitoring response to therapy'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H3260777503">
         <span class="h1">
          SOCIETY GUIDELINE LINKS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See
         <a class="medical medical_society_guidelines" href="/z/d/html/113808.html" rel="external">
          "Society guideline links: Thyroid nodules and cancer"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H18">
         <span class="h1">
          SUMMARY AND RECOMMENDATIONS
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Utility of thyroglobulin
         </strong>
         – Thyroglobulin (Tg) is a storage form of thyroxine (T4) and triiodothyronine (T3). It is synthesized only by thyroid follicular cells and released into serum along with the thyroid hormones. Given the cellular specificity of Tg, its detection in biopsy specimens provides proof of the thyroid origin of the tissue. Serum Tg provides important information about the presence or absence of residual, recurrent, or metastatic disease in patients with differentiated thyroid cancer. In addition, serum Tg concentrations may predict disease-free remission at various times in the patient's course. (See
         <a class="local">
          'Introduction'
         </a>
         above and
         <a class="local">
          'Monitoring response to therapy'
         </a>
         above and
         <a class="medical medical_review" href="/z/d/html/7838.html" rel="external">
          "Differentiated thyroid cancer: Overview of management", section on 'Monitoring response to therapy'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Thyroglobulin assay
         </strong>
         – Testing of serum Tg should be done using a sensitive assay, ideally using the same assay for each sample. Limitations to serum Tg assays include interassay variability and assay interference by antithyroglobulin (anti-Tg) antibodies, which are highly prevalent in the population. (See
         <a class="local">
          'Thyroglobulin assay'
         </a>
         above and
         <a class="local">
          'Thyroglobulin antibodies'
         </a>
         above and
         <a class="local">
          'Monitoring response to therapy'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Thyroglobulin antibodies
         </strong>
         – Tg antibodies should always be measured with Tg, using the same Tg antibody assay over time. In patients with anti-Tg antibodies, serum Tg concentrations alone cannot be used as a marker to detect persistent or recurrent disease after thyroidectomy and ablation of residual normal thyroid tissue. Nevertheless, disease recurrence can be heralded by a rise in Tg antibodies with or without a corresponding rise in serum Tg. (See
         <a class="local">
          'Surrogate tumor marker'
         </a>
         above and
         <a class="medical medical_review" href="/z/d/html/7838.html" rel="external">
          "Differentiated thyroid cancer: Overview of management", section on 'Thyroglobulin antibodies'
         </a>
         .)
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li>
          <a class="nounderline abstract_t">
           Spencer CA, Bergoglio LM, Kazarosyan M, et al. Clinical impact of thyroglobulin (Tg) and Tg autoantibody method differences on the management of patients with differentiated thyroid carcinomas. J Clin Endocrinol Metab 2005; 90:5566.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Spencer CA, Takeuchi M, Kazarosyan M. Current status and performance goals for serum thyrotropin (TSH) assays. Clin Chem 1996; 42:140.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Weightman DR, Mallick UK, Fenwick JD, Perros P. Discordant serum thyroglobulin results generated by two classes of assay in patients with thyroid carcinoma: correlation with clinical outcome after 3 years of follow-up. Cancer 2003; 98:41.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Schlumberger M, Hitzel A, Toubert ME, et al. Comparison of seven serum thyroglobulin assays in the follow-up of papillary and follicular thyroid cancer patients. J Clin Endocrinol Metab 2007; 92:2487.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Schulz R, Bethäuser H, Stempka L, et al. Evidence for immunological differences between circulating and thyroid tissue-derived thyroglobulin in men. Eur J Clin Invest 1989; 19:459.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bertaux F, Noel M, Malthiéry Y, Fragu P. Demonstration of a heterogeneous transcription pattern of thyroglobulin mRNA in human thyroid tissues. Biochem Biophys Res Commun 1991; 178:586.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sinadinović J, Cvejić D, Savin S, et al. Altered terminal glycosylation of thyroglobulin in papillary thyroid carcinoma. Exp Clin Endocrinol 1992; 100:124.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Demers LM, Spencer CA. Laboratory medicine practice guidelines: laboratory support for the diagnosis and monitoring of thyroid disease. Clin Endocrinol (Oxf) 2003; 58:138.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Spencer C, Fatemi S, Singer P, et al. Serum Basal thyroglobulin measured by a second-generation assay correlates with the recombinant human thyrotropin-stimulated thyroglobulin response in patients treated for differentiated thyroid cancer. Thyroid 2010; 20:587.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Garo ML, Campennì A, Petranovic-Ovcaricek P, et al. Evolution of thyroid cancer biomarkers: from laboratory test to patients' clinical management. Clin Chem Lab Med 2023; 61:935.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Giovanella L, Duntas LH. MANAGEMENT OF ENDOCRINE DISEASE: The role of rhTSH in the management of differentiated thyroid cancer: pros and cons. Eur J Endocrinol 2019; 181:R133.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mazzaferri EL, Robbins RJ, Spencer CA, et al. A consensus report of the role of serum thyroglobulin as a monitoring method for low-risk patients with papillary thyroid carcinoma. J Clin Endocrinol Metab 2003; 88:1433.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Smallridge RC, Meek SE, Morgan MA, et al. Monitoring thyroglobulin in a sensitive immunoassay has comparable sensitivity to recombinant human tsh-stimulated thyroglobulin in follow-up of thyroid cancer patients. J Clin Endocrinol Metab 2007; 92:82.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Iervasi A, Iervasi G, Ferdeghini M, et al. Clinical relevance of highly sensitive Tg assay in monitoring patients treated for differentiated thyroid cancer. Clin Endocrinol (Oxf) 2007; 67:434.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rosario PW, Purisch S. Does a highly sensitive thyroglobulin (Tg) assay change the clinical management of low-risk patients with thyroid cancer with Tg on T4 &lt; 1 ng/ml determined by traditional assays? Clin Endocrinol (Oxf) 2008; 68:338.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Giovanella L. Circulating biomarkers for the detection of tumor recurrence in the postsurgical follow-up of differentiated thyroid carcinoma. Curr Opin Oncol 2020; 32:7.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cole TG, Johnson D, Eveland BJ, Nahm MH. Cost-effective method for detection of "hook effect" in tumor marker immunometric assays. Clin Chem 1993; 39:695.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Preissner CM, O'Kane DJ, Singh RJ, et al. Phantoms in the assay tube: heterophile antibody interferences in serum thyroglobulin assays. J Clin Endocrinol Metab 2003; 88:3069.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ding L, Shankara-Narayana N, Wood C, et al. Markedly elevated serum thyroglobulin associated with heterophile antibodies: a cautionary tale. Thyroid 2013; 23:771.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Spencer CA, Lopresti JS. Measuring thyroglobulin and thyroglobulin autoantibody in patients with differentiated thyroid cancer. Nat Clin Pract Endocrinol Metab 2008; 4:223.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ylli D, Soldin SJ, Stolze B, et al. Biotin Interference in Assays for Thyroid Hormones, Thyrotropin and Thyroglobulin. Thyroid 2021; 31:1160.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hollowell JG, Staehling NW, Flanders WD, et al. Serum TSH, T(4), and thyroid antibodies in the United States population (1988 to 1994): National Health and Nutrition Examination Survey (NHANES III). J Clin Endocrinol Metab 2002; 87:489.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Spencer CA, Takeuchi M, Kazarosyan M, et al. Serum thyroglobulin autoantibodies: prevalence, influence on serum thyroglobulin measurement, and prognostic significance in patients with differentiated thyroid carcinoma. J Clin Endocrinol Metab 1998; 83:1121.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Verburg FA, Luster M, Cupini C, et al. Implications of thyroglobulin antibody positivity in patients with differentiated thyroid cancer: a clinical position statement. Thyroid 2013; 23:1211.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Piechaczyk M, Baldet L, Pau B, Bastide JM. Novel immunoradiometric assay of thyroglobulin in serum with use of monoclonal antibodies selected for lack of cross-reactivity with autoantibodies. Clin Chem 1989; 35:422.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Spencer C, Petrovic I, Fatemi S. Current thyroglobulin autoantibody (TgAb) assays often fail to detect interfering TgAb that can result in the reporting of falsely low/undetectable serum Tg IMA values for patients with differentiated thyroid cancer. J Clin Endocrinol Metab 2011; 96:1283.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Clarke NJ, Zhang Y, Reitz RE. A novel mass spectrometry-based assay for the accurate measurement of thyroglobulin from patient samples containing antithyroglobulin autoantibodies. J Investig Med 2012; 60:1157.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Netzel BC, Grebe SK, Carranza Leon BG, et al. Thyroglobulin (Tg) Testing Revisited: Tg Assays, TgAb Assays, and Correlation of Results With Clinical Outcomes. J Clin Endocrinol Metab 2015; 100:E1074.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Spencer C, Petrovic I, Fatemi S, LoPresti J. Serum thyroglobulin (Tg) monitoring of patients with differentiated thyroid cancer using sensitive (second-generation) immunometric assays can be disrupted by false-negative and false-positive serum thyroglobulin autoantibody misclassifications. J Clin Endocrinol Metab 2014; 99:4589.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Spencer C, Fatemi S. Thyroglobulin antibody (TgAb) methods - Strengths, pitfalls and clinical utility for monitoring TgAb-positive patients with differentiated thyroid cancer. Best Pract Res Clin Endocrinol Metab 2013; 27:701.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Spencer C, LoPresti J, Fatemi S. How sensitive (second-generation) thyroglobulin measurement is changing paradigms for monitoring patients with differentiated thyroid cancer, in the absence or presence of thyroglobulin autoantibodies. Curr Opin Endocrinol Diabetes Obes 2014; 21:394.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kim WG, Yoon JH, Kim WB, et al. Change of serum antithyroglobulin antibody levels is useful for prediction of clinical recurrence in thyroglobulin-negative patients with differentiated thyroid carcinoma. J Clin Endocrinol Metab 2008; 93:4683.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chung JK, Park YJ, Kim TY, et al. Clinical significance of elevated level of serum antithyroglobulin antibody in patients with differentiated thyroid cancer after thyroid ablation. Clin Endocrinol (Oxf) 2002; 57:215.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Côrtes MCS, Rosario PW, Oliveira LFF, Calsolari MR. Clinical Impact of Detectable Antithyroglobulin Antibodies Below the Reference Limit (Borderline) in Patients with Papillary Thyroid Carcinoma with Undetectable Serum Thyroglobulin and Normal Neck Ultrasonography After Ablation: A Prospective Study. Thyroid 2018; 28:229.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Yin N, Sherman SI, Pak Y, et al. The De Novo Detection of Anti-Thyroglobulin Antibodies and Differentiated Thyroid Cancer Recurrence. Thyroid 2020; 30:1490.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Spencer CA. Clinical review: Clinical utility of thyroglobulin antibody (TgAb) measurements for patients with differentiated thyroid cancers (DTC). J Clin Endocrinol Metab 2011; 96:3615.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chiovato L, Latrofa F, Braverman LE, et al. Disappearance of humoral thyroid autoimmunity after complete removal of thyroid antigens. Ann Intern Med 2003; 139:346.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Taïeb D, Lussato D, Guedj E, et al. Early sequential changes in serum thyroglobulin after radioiodine ablation for thyroid cancer: possible clinical implications for recombinant human thyrotropin-aided therapy. Thyroid 2006; 16:177.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Giovanella L, Ceriani L, Maffioli M. Postsurgery serum thyroglobulin disappearance kinetic in patients with differentiated thyroid carcinoma. Head Neck 2010; 32:568.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Robbins RJ, Srivastava S, Shaha A, et al. Factors influencing the basal and recombinant human thyrotropin-stimulated serum thyroglobulin in patients with metastatic thyroid carcinoma. J Clin Endocrinol Metab 2004; 89:6010.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Eustatia-Rutten CF, Smit JW, Romijn JA, et al. Diagnostic value of serum thyroglobulin measurements in the follow-up of differentiated thyroid carcinoma, a structured meta-analysis. Clin Endocrinol (Oxf) 2004; 61:61.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pacini F, Molinaro E, Castagna MG, et al. Recombinant human thyrotropin-stimulated serum thyroglobulin combined with neck ultrasonography has the highest sensitivity in monitoring differentiated thyroid carcinoma. J Clin Endocrinol Metab 2003; 88:3668.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ozata M, Suzuki S, Miyamoto T, et al. Serum thyroglobulin in the follow-up of patients with treated differentiated thyroid cancer. J Clin Endocrinol Metab 1994; 79:98.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lo Gerfo P, Colacchio TA, Colacchio DA, Feind CR. Effect of TSH stimulation on serum thyroglobulin in metastatic thyroid cancer. J Surg Oncol 1980; 14:195.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pacini F, Lari R, Mazzeo S, et al. Diagnostic value of a single serum thyroglobulin determination on and off thyroid suppressive therapy in the follow-up of patients with differentiated thyroid cancer. Clin Endocrinol (Oxf) 1985; 23:405.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chou R, Dana T, Brent GA, et al. Serum Thyroglobulin Measurement Following Surgery Without Radioactive Iodine for Differentiated Thyroid Cancer: A Systematic Review. Thyroid 2022; 32:613.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pelttari H, Laitinen K, Schalin-Jäntti C, Välimäki MJ. Long-term outcome of 495 TNM stage I or II patients with differentiated thyroid carcinoma followed up with neck ultrasonography and thyroglobulin measurements on T4 treatment. Clin Endocrinol (Oxf) 2008; 69:323.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Castagna MG, Brilli L, Pilli T, et al. Limited value of repeat recombinant human thyrotropin (rhTSH)-stimulated thyroglobulin testing in differentiated thyroid carcinoma patients with previous negative rhTSH-stimulated thyroglobulin and undetectable basal serum thyroglobulin levels. J Clin Endocrinol Metab 2008; 93:76.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Baudin E, Do Cao C, Cailleux AF, et al. Positive predictive value of serum thyroglobulin levels, measured during the first year of follow-up after thyroid hormone withdrawal, in thyroid cancer patients. J Clin Endocrinol Metab 2003; 88:1107.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Heemstra KA, Liu YY, Stokkel M, et al. Serum thyroglobulin concentrations predict disease-free remission and death in differentiated thyroid carcinoma. Clin Endocrinol (Oxf) 2007; 66:58.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kim TY, Kim WB, Kim ES, et al. Serum thyroglobulin levels at the time of 131I remnant ablation just after thyroidectomy are useful for early prediction of clinical recurrence in low-risk patients with differentiated thyroid carcinoma. J Clin Endocrinol Metab 2005; 90:1440.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Webb RC, Howard RS, Stojadinovic A, et al. The utility of serum thyroglobulin measurement at the time of remnant ablation for predicting disease-free status in patients with differentiated thyroid cancer: a meta-analysis involving 3947 patients. J Clin Endocrinol Metab 2012; 97:2754.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kloos RT, Mazzaferri EL. A single recombinant human thyrotropin-stimulated serum thyroglobulin measurement predicts differentiated thyroid carcinoma metastases three to five years later. J Clin Endocrinol Metab 2005; 90:5047.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Black EG, Sheppard MC, Hoffenberg R. Serial serum thyroglobulin measurements in the management of differentiated thyroid carcinoma. Clin Endocrinol (Oxf) 1987; 27:115.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Huang SH, Wang PW, Huang YE, et al. Sequential follow-up of serum thyroglobulin and whole body scan in thyroid cancer patients without initial metastasis. Thyroid 2006; 16:1273.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Miyauchi A, Kudo T, Miya A, et al. Prognostic impact of serum thyroglobulin doubling-time under thyrotropin suppression in patients with papillary thyroid carcinoma who underwent total thyroidectomy. Thyroid 2011; 21:707.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 2193 Version 18.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15985472" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : Clinical impact of thyroglobulin (Tg) and Tg autoantibody method differences on the management of patients with differentiated thyroid carcinomas.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8565217" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : Current status and performance goals for serum thyrotropin (TSH) assays.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12833453" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : Discordant serum thyroglobulin results generated by two classes of assay in patients with thyroid carcinoma: correlation with clinical outcome after 3 years of follow-up.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17426102" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : Comparison of seven serum thyroglobulin assays in the follow-up of papillary and follicular thyroid cancer patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2479559" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : Evidence for immunological differences between circulating and thyroid tissue-derived thyroglobulin in men.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1859419" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : Demonstration of a heterogeneous transcription pattern of thyroglobulin mRNA in human thyroid tissues.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1305063" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : Altered terminal glycosylation of thyroglobulin in papillary thyroid carcinoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12580927" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : Laboratory medicine practice guidelines: laboratory support for the diagnosis and monitoring of thyroid disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20470203" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : Serum Basal thyroglobulin measured by a second-generation assay correlates with the recombinant human thyrotropin-stimulated thyroglobulin response in patients treated for differentiated thyroid cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/36370420" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : Evolution of thyroid cancer biomarkers: from laboratory test to patients' clinical management.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31252412" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : MANAGEMENT OF ENDOCRINE DISEASE: The role of rhTSH in the management of differentiated thyroid cancer: pros and cons.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12679418" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : A consensus report of the role of serum thyroglobulin as a monitoring method for low-risk patients with papillary thyroid carcinoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17077133" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : Monitoring thyroglobulin in a sensitive immunoassay has comparable sensitivity to recombinant human tsh-stimulated thyroglobulin in follow-up of thyroid cancer patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17555505" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : Clinical relevance of highly sensitive Tg assay in monitoring patients treated for differentiated thyroid cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17850379" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : Does a highly sensitive thyroglobulin (Tg) assay change the clinical management of low-risk patients with thyroid cancer with Tg on T4&lt;1 ng/ml determined by traditional assays?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31599768" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : Circulating biomarkers for the detection of tumor recurrence in the postsurgical follow-up of differentiated thyroid carcinoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8472372" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : Cost-effective method for detection of "hook effect" in tumor marker immunometric assays.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12843145" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : Phantoms in the assay tube: heterophile antibody interferences in serum thyroglobulin assays.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23294194" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : Markedly elevated serum thyroglobulin associated with heterophile antibodies: a cautionary tale.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18268520" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : Measuring thyroglobulin and thyroglobulin autoantibody in patients with differentiated thyroid cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34042535" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : Biotin Interference in Assays for Thyroid Hormones, Thyrotropin and Thyroglobulin.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11836274" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : Serum TSH, T(4), and thyroid antibodies in the United States population (1988 to 1994): National Health and Nutrition Examination Survey (NHANES III).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9543128" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : Serum thyroglobulin autoantibodies: prevalence, influence on serum thyroglobulin measurement, and prognostic significance in patients with differentiated thyroid carcinoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23692026" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : Implications of thyroglobulin antibody positivity in patients with differentiated thyroid cancer: a clinical position statement.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2465845" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : Novel immunoradiometric assay of thyroglobulin in serum with use of monoclonal antibodies selected for lack of cross-reactivity with autoantibodies.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21325460" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : Current thyroglobulin autoantibody (TgAb) assays often fail to detect interfering TgAb that can result in the reporting of falsely low/undetectable serum Tg IMA values for patients with differentiated thyroid cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23138009" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : A novel mass spectrometry-based assay for the accurate measurement of thyroglobulin from patient samples containing antithyroglobulin autoantibodies.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26079778" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : Thyroglobulin (Tg) Testing Revisited: Tg Assays, TgAb Assays, and Correlation of Results With Clinical Outcomes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25226290" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : Serum thyroglobulin (Tg) monitoring of patients with differentiated thyroid cancer using sensitive (second-generation) immunometric assays can be disrupted by false-negative and false-positive serum thyroglobulin autoantibody misclassifications.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24094640" id="rid29" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          30 : Thyroglobulin antibody (TgAb) methods - Strengths, pitfalls and clinical utility for monitoring TgAb-positive patients with differentiated thyroid cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25122493" id="rid30" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          31 : How sensitive (second-generation) thyroglobulin measurement is changing paradigms for monitoring patients with differentiated thyroid cancer, in the absence or presence of thyroglobulin autoantibodies.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18812478" id="rid31" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          32 : Change of serum antithyroglobulin antibody levels is useful for prediction of clinical recurrence in thyroglobulin-negative patients with differentiated thyroid carcinoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12153600" id="rid32" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          33 : Clinical significance of elevated level of serum antithyroglobulin antibody in patients with differentiated thyroid cancer after thyroid ablation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29325506" id="rid33" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          34 : Clinical Impact of Detectable Antithyroglobulin Antibodies Below the Reference Limit (Borderline) in Patients with Papillary Thyroid Carcinoma with Undetectable Serum Thyroglobulin and Normal Neck Ultrasonography After Ablation: A Prospective Study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32228151" id="rid34" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          35 : The De Novo Detection of Anti-Thyroglobulin Antibodies and Differentiated Thyroid Cancer Recurrence.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21917876" id="rid35" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          36 : Clinical review: Clinical utility of thyroglobulin antibody (TgAb) measurements for patients with differentiated thyroid cancers (DTC).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12965943" id="rid36" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          37 : Disappearance of humoral thyroid autoimmunity after complete removal of thyroid antigens.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16676403" id="rid37" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          38 : Early sequential changes in serum thyroglobulin after radioiodine ablation for thyroid cancer: possible clinical implications for recombinant human thyrotropin-aided therapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19672965" id="rid38" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          39 : Postsurgery serum thyroglobulin disappearance kinetic in patients with differentiated thyroid carcinoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15579752" id="rid39" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          40 : Factors influencing the basal and recombinant human thyrotropin-stimulated serum thyroglobulin in patients with metastatic thyroid carcinoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15212646" id="rid40" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          41 : Diagnostic value of serum thyroglobulin measurements in the follow-up of differentiated thyroid carcinoma, a structured meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12915653" id="rid41" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          42 : Recombinant human thyrotropin-stimulated serum thyroglobulin combined with neck ultrasonography has the highest sensitivity in monitoring differentiated thyroid carcinoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8027262" id="rid42" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          43 : Serum thyroglobulin in the follow-up of patients with treated differentiated thyroid cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7392641" id="rid43" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          44 : Effect of TSH stimulation on serum thyroglobulin in metastatic thyroid cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/4064348" id="rid44" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          45 : Diagnostic value of a single serum thyroglobulin determination on and off thyroid suppressive therapy in the follow-up of patients with differentiated thyroid cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35412871" id="rid45" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          46 : Serum Thyroglobulin Measurement Following Surgery Without Radioactive Iodine for Differentiated Thyroid Cancer: A Systematic Review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18284635" id="rid46" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          47 : Long-term outcome of 495 TNM stage I or II patients with differentiated thyroid carcinoma followed up with neck ultrasonography and thyroglobulin measurements on T4 treatment.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17971424" id="rid47" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          48 : Limited value of repeat recombinant human thyrotropin (rhTSH)-stimulated thyroglobulin testing in differentiated thyroid carcinoma patients with previous negative rhTSH-stimulated thyroglobulin and undetectable basal serum thyroglobulin levels.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12629092" id="rid48" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          49 : Positive predictive value of serum thyroglobulin levels, measured during the first year of follow-up after thyroid hormone withdrawal, in thyroid cancer patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17201802" id="rid49" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          50 : Serum thyroglobulin concentrations predict disease-free remission and death in differentiated thyroid carcinoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15613412" id="rid50" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          51 : Serum thyroglobulin levels at the time of 131I remnant ablation just after thyroidectomy are useful for early prediction of clinical recurrence in low-risk patients with differentiated thyroid carcinoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22639291" id="rid51" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          52 : The utility of serum thyroglobulin measurement at the time of remnant ablation for predicting disease-free status in patients with differentiated thyroid cancer: a meta-analysis involving 3947 patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15972576" id="rid52" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          53 : A single recombinant human thyrotropin-stimulated serum thyroglobulin measurement predicts differentiated thyroid carcinoma metastases three to five years later.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3652482" id="rid53" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          54 : Serial serum thyroglobulin measurements in the management of differentiated thyroid carcinoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17199438" id="rid54" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          55 : Sequential follow-up of serum thyroglobulin and whole body scan in thyroid cancer patients without initial metastasis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21649472" id="rid55" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          56 : Prognostic impact of serum thyroglobulin doubling-time under thyrotropin suppression in patients with papillary thyroid carcinoma who underwent total thyroidectomy.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
